Clinical Implications of Emerging Data on B7-H3–directed ADCs in the Future of ES-SCLC

https://is1-ssl.mzstatic.com/image/thumb/Podcasts125/v4/54/f0/ac/54f0ac5d-ba46-f9e7-28b7-672ab0a048c7/mza_5551349009705862383.jpg/600x600bb.jpg

ReachMD CME

ReachMD

404 episodes

1 day ago

Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, cardiology, women's health and more. And our CME library is continuously growing, every quarter.

Science

Medicine

RSS

All content for ReachMD CME is the property of ReachMD and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Science

Medicine

Clinical Implications of Emerging Data on B7-H3–directed ADCs in the Future of ES-SCLC

ReachMD CME

1 month ago

Clinical Implications of Emerging Data on B7-H3–directed ADCs in the Future of ES-SCLC

CME credits: 0.50
Valid until: 11-11-2026
Claim your CME credit at https://reachmd.com/programs/cme/clinical-implications-of-emerging-data-on-b7-h3directed-adcs-in-the-future-of-es-sclc/39979/

This online CME program will provide the latest clinical updates on B7-H3–directed antibody-drug conjugates (ADCs) in extensive-stage small cell lung cancer (ES-SCLC). Faculty experts will review the biological rationale for targeting B7-H3 in ES-SCLC and discuss recent clinical evidence on B7-H3 ADCs presented at WCLC and ESMO 2025. Participants will gain practical insights on selecting appropriate patients for B7-H3 ADCs, including efficacy and safety considerations. The program will equip oncology professionals with evidence-based strategies to integrate emerging B7-H3 ADCs into multidisciplinary care for ES-SCLC when they become available.